Paper Details

  1. Home
  2. Paper Details

Treatment of acute duodenal ulcers with famotidine and its comparison with other H2 blockers.

Author: AkhtarM A, KhanM A, RashidP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Famotidine (40 mg qhs) was effective and generally well-tolerated in the treatment of acute duodenal ulcer.
Paper Details　
Original Abstract of the Article :
Famotidine, a new H2 antagonist in a dose of 40 mg qhs was tried in a clinical trial for the treatment of duodenal ulcer in 25 patients and compared with other H2 antagonists. Cimetidine 800 mg qhs and Ranitidine 300 mg qhs were used in a similar number of randomised patients. Patients were evaluate...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1975277

データ提供：米国国立医学図書館（NLM）

Famotidine: A New Hope in the Treatment of Duodenal Ulcers

The field of gastroenterology is constantly seeking new and effective treatments for digestive disorders. This study explores the efficacy and safety of famotidine, a new H2 antagonist, in the treatment of acute duodenal ulcers. The researchers compared the healing rates of famotidine, cimetidine, and ranitidine in patients with duodenal ulcers, finding that famotidine demonstrated comparable efficacy with a low incidence of side effects. The study's findings suggest that famotidine may be a valuable addition to the gastroenterologist's arsenal for treating duodenal ulcers, offering a potentially more effective and well-tolerated option compared to existing H2 antagonists.

A New Oasis in the Desert of Duodenal Ulcers: Famotidine Offers Promise

The study reveals that famotidine may be a promising new treatment option for duodenal ulcers, offering a potential alternative to existing H2 antagonists. It's like discovering a new oasis in the vast desert of gastrointestinal disorders – a place of respite and healing for those struggling with debilitating ulcers. The study's findings suggest that famotidine may be an effective and well-tolerated treatment, offering hope for patients seeking relief from their symptoms.

Navigating the Sands of Duodenal Ulcers: Famotidine as a Potential Treatment

This study provides valuable insights into the potential benefits of famotidine for treating duodenal ulcers. It's like navigating a challenging desert journey – understanding the various treatment options and choosing the right path can significantly impact the outcome of the journey. The study's findings suggest that famotidine may be a safe and effective alternative to existing H2 antagonists, offering hope for patients seeking relief from their symptoms and a smoother path to recovery.

Dr.Camel's Conclusion

This study highlights the potential of famotidine as a promising new treatment option for acute duodenal ulcers. It's a reminder that the field of gastroenterology is constantly evolving, seeking new and effective treatments for digestive disorders. The study's findings suggest that famotidine may be a valuable addition to the gastroenterologist's arsenal, offering patients a potentially more effective and well-tolerated option for treating duodenal ulcers.

Date :
  1. Date Completed 1990-10-02
  2. Date Revised 2016-10-18
Further Info :

Pubmed ID

1975277

DOI: Digital Object Identifier

5440

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.